Results 181 to 190 of about 101,617 (297)

Can DPP-4 Inhibitors Improve Glycemic Control and Preserve Beta-Cell Function in Type 1 Diabetes Mellitus? A Systematic Review. [PDF]

Diseases
Villa Chagas H, Laurindo LF, Dogani Rodrigues V, Haber JFDS, Chagas EFB, Barbalho SM.   +5 more
europepmc   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source

Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease. [PDF]

Diabetes Res Clin Pract
Hong AT, Lin F, Luu IY, Shin L, Han SM, Armstrong DG, Tan TW.   +6 more
europepmc   +1 more source

Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice

Journal of Diabetes Investigation, EarlyView.
Liraglutide combined with Dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice. Diabetic cardiomyopathy (DCM) and endothelial dysfunction were established in mice via HFD and STZ injection. The combination therapy of Liraglutide and Dapagliflozin synergistically improved metabolic parameters and attenuated ...
An‐Jun Tan, Tian‐Rong Li, Jing‐Jing Yang, Xiao‐Lu Li, Wen‐Qin Li, Jin‐Wen Yu   +5 more
wiley   +1 more source

Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials. [PDF]

Int J Mol Sci
Hung CM, Hsu CW, Zeng BS, Suen MW, Chen JJ, Zeng BY, Carvalho AF, Stubbs B, Chen YW, Chen TY, Hsu SP, Wang HY, Liang CS, Tu YK, Tseng PT.   +14 more
europepmc   +1 more source

Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real‐world observational study

Journal of Diabetes Investigation, EarlyView.
This real‐world observational study enrolled 256 patients with type 2 diabetes and chronic kidney disease (T2D‐CKD). After 12 months of finerenone treatment, 45 patients completed follow‐up. Finerenone was associated with significant improvements in insulin resistance markers (HOMA‐IR, TyG index), lipid profile (LDL‐C), glycemic control (HbA1c), and ...
Xin Zhao, Bohan Liu, Ran Sun, Yaxuan Shi, Ya Liu   +4 more
wiley   +1 more source

NeSyDPP-4: discovering DPP-4 inhibitors for diabetes treatment with a neuro-symbolic AI approach. [PDF]

Front Bioinform
Hossain D, Saghapour E, Chen JY.
europepmc   +1 more source

Associations of skeletal muscle mass and strength with arterial stiffness in type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
Lower skeletal muscle mass and lower handgrip strength were associated with higher arterial stiffness in individuals with type 2 diabetes. Assessment of both parameters may provide complementary information regarding vascular risk. ABSTRACT Sarcopenia is prevalent in people with type 2 diabetes mellitus (T2DM) and may contribute to increased ...
Naoki Koike, Yoko Irie, Yuji Doi, Ryosuke Kemmotsu, Moe Kusushita, Yasuna Sakai, Tomonori Okita, Hiroyuki Sho, Ryoko Inui, Yukiko Tabuchi, Tetsuyuki Yasuda   +10 more
wiley   +1 more source

Comparative Efficacy, Safety, and Cost-Utility of DPP-4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real-World Clinical and Economic Outcomes. [PDF]

J Diabetes Res
Jimoh AO, Hudu SA, Sabir AA, Adamu AA, Bello N, Tahir A, Abubakar N.   +6 more
europepmc   +1 more source

Adaptive islet biology and comprehensive incretin physiology: Emerging perspectives from Asia and Europe

Journal of Diabetes Investigation, EarlyView.
Adaptive islet biology and incretin physiology provide a framework linking diverse diabetes phenotypes, with advances in β‐cell stress adaptation, intra‐islet communication, receptor‐resolved biology, and β‐cell mass imaging. By integrating clinical perspectives from Asia and Europe with multiscale islet‐cell biology, these insights may support ...
Takaaki Murakami, Daniela Nasteska, David J. Hodson, Yuji Yamazaki, Daisuke Yabe, Yutaka Seino   +5 more
wiley   +1 more source